Synlogic⢠is pioneering the development of a novel class of living Synthetic Biotic⢠medicines based on its proprietary drug discovery and development platform. Synlogicâs initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit synlogictx.com. Source
No articles found.
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutio...
Allscripts (NASDAQ: MDRX) is a leader in health...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and d...
Cocrystal Pharma, Inc. is a clinical stage biot...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Join the National Investor Network and get the latest information with your interests in mind.